FLUOGUIDE A/S DK -1 (96X) - Total Assets
Based on the latest financial reports, FLUOGUIDE A/S DK -1 (96X) holds total assets worth €88.29 Million EUR (≈ $103.22 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 96X total equity for net asset value and shareholders' equity analysis.
FLUOGUIDE A/S DK -1 - Total Assets Trend (2021–2025)
This chart illustrates how FLUOGUIDE A/S DK -1's total assets have evolved over time, based on quarterly financial data.
FLUOGUIDE A/S DK -1 - Asset Composition Analysis
Current Asset Composition (December 2025)
FLUOGUIDE A/S DK -1's total assets of €88.29 Million consist of 98.3% current assets and 1.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 55.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €378.00K | 0.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how FLUOGUIDE A/S DK -1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see FLUOGUIDE A/S DK -1 (96X) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: FLUOGUIDE A/S DK -1's current assets represent 98.3% of total assets in 2025, a decrease from 99.1% in 2021.
- Cash Position: Cash and equivalents constituted 55.3% of total assets in 2025, down from 87.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 0.4% of total assets.
FLUOGUIDE A/S DK -1 Competitors by Total Assets
Key competitors of FLUOGUIDE A/S DK -1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
FLUOGUIDE A/S DK -1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.15 | 5.39 | 11.48 |
| Quick Ratio | 15.15 | 5.39 | 11.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €81.02 Million | €21.59 Million | €30.03 Million |
FLUOGUIDE A/S DK -1 - Advanced Valuation Insights
This section examines the relationship between FLUOGUIDE A/S DK -1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.35 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 211.1% |
| Total Assets | €88.29 Million |
| Market Capitalization | $57.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values FLUOGUIDE A/S DK -1's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: FLUOGUIDE A/S DK -1's assets grew by 211.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for FLUOGUIDE A/S DK -1 (2021–2025)
The table below shows the annual total assets of FLUOGUIDE A/S DK -1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €88.29 Million ≈ $103.22 Million |
+211.11% |
| 2024-12-31 | €28.38 Million ≈ $33.18 Million |
-4.15% |
| 2023-12-31 | €29.61 Million ≈ $34.62 Million |
-16.88% |
| 2022-12-31 | €35.62 Million ≈ $41.64 Million |
-33.18% |
| 2021-12-31 | €53.31 Million ≈ $62.32 Million |
-- |
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more